Insider sales are small relative to market cap and may reflect routine portfolio rebalancing after a strong earnings report. Monitor for any additional insider selling in the coming weeks; if sales accelerate, it could signal reduced confidence in the sustainability of the recent margin expansion.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $42.97entry
- T+1 · 7d ago −1.33%α −0.96% · $42.40
- T+5 · 16h ago −0.93%α +0.76% · $42.57
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Teva insiders sold shares in the open market days after the company reported a Q3 2026 earnings beat and raised guidance. The combined $2.29M in sales is modest relative to Teva's market cap, but the timing and absence of 10b5-1 plans suggest potential profit-taking after the stock's post-earnings strength.
Key Financial Metrics
Key Facts
- Two insiders sold a combined $2.29M in open-market sales on Nov 4-5, 2026
- Sales followed Teva's Q3 2026 earnings beat (non-GAAP EPS $0.86 vs $0.72 consensus) and raised 2026 revenue outlook
- Neither sale was executed under a 10b5-1 plan
- Total sales represent approximately 0.07% of Teva's market cap (estimated ~$3.3B based on ~79M shares at $41.72)
- Interim Chief Legal Officer Bergwerk Dov also exercised derivatives on Nov 4, acquiring shares at $0-$34.70, then sold a portion at $41.72
Financial Impact
Total open-market sales of $2.29M, about 0.07% of market cap
Risk Factors
- Insider sales occurred immediately after a positive earnings release, which could be interpreted as profit-taking rather than a negative signal
- Sales are small relative to market cap, limiting their informational value
- No 10b5-1 plans were used, but the sales could still be part of a pre-arranged plan not disclosed in the Form 4
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TEVA-1794517709495 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Viewing Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers